Invention Title:

CHIMERIC ANTIGEN RECEPTORS TARGETING CD19 AND USE THEREOF

Publication number:

US20260325637

Publication date:
Section:

Human necessities

Class:

A61K40/31

Inventors:

Assignees:

Applicants:

Smart overview of the Invention

The patent application discusses chimeric antigen receptors (CARs) that are specifically designed to target CD19, a protein commonly found on the surface of certain cancer cells. These CARs are incorporated into immune cells, enabling them to recognize and attack CD19-expressing cells, which is particularly useful in treating blood cancers. The application outlines the structure of these CARs and provides details on their potential therapeutic applications.

Technical Field

This invention falls within the field of cancer treatment using immunotherapy. It focuses on the use of genetically modified cells that express CARs targeting CD19 to treat neoplasms, such as blood cancers. By utilizing these engineered cells, the approach aims to enhance the body's immune response against cancerous cells.

Background

Cell-based immunotherapy, particularly using CAR T-cells, has emerged as a promising treatment for cancer. CARs are synthetic receptors introduced into T-cells, allowing them to target specific tumor antigens. Previous studies have shown success in targeting B-cell malignancies using CARs derived from murine antibodies. However, these can induce immune responses in humans, leading to the premature destruction of CAR T-cells and potential tumor relapse. Therefore, there is a need for improved CARs with reduced immunogenicity and enhanced safety and efficacy.

Summary of Invention

The application details the construction of CD19-targeted CARs, specifying the components such as the extracellular antigen-binding domain, transmembrane domain, and intracellular signaling domain. The antigen-binding domain can include various forms like single-chain variable fragments (scFv), and specific sequences are provided for both heavy and light chain variable regions. These sequences are designed to minimize immunogenicity while maintaining effective targeting of CD19.

Implementation Details

The detailed sequence information provided in the application allows for the precise construction of CARs with humanized scFvs, which are less likely to provoke immune responses. Multiple configurations of the variable regions are described, each with specific amino acid sequences that enhance the CAR's ability to bind to CD19. This meticulous design aims to optimize the therapeutic potential of the CARs, offering a more effective and safer treatment option for patients with CD19-positive cancers.